Volpara Debuts Enhanced Breast Imaging Metrics
Volpara to present at RSNA 2014 next generation of VolparaAnalytics.
Volpara will showcase at RSNA 2014 VolparaAnalytics version 1.2.
Volpara Analytics is a centralized dashboard that presents key mammography metrics and automatically collates data from digital mammography and tomosynthesis units to enable cross-comparison of patient populations, mammography systems, and operator performance, Volpara said.
The new version of VolparaAnalytics will feature an enhanced user interface and reporting tools, and deliver expanded breast imaging metrics to users including additional quality metrics, new temporal analysis tools, additional tools to analyze patient positioning and patient dose, and time between study acquisition, Volpara said.
VolparaAnalytics runs on top of VolparaDensity, a software tool that helps radiologists objectively assess density from both digital mammography and tomosynthesis images and determine which women would benefit from additional screening.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
